Albert Lowe
Stock Analyst at Craig-Hallum
(2.13)
# 2,886
Out of 5,114 analysts
10
Total ratings
30%
Success rate
6.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $99.73 | +75.47% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $20.55 | +143.31% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.73 | +447.12% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $2.00 | +200.00% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $0.93 | +1,405.38% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.99 | +175.69% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.57 | +211.28% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.68 | +138.10% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.24 | +383.87% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $99.73
Upside: +75.47%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $20.55
Upside: +143.31%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.73
Upside: +447.12%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $2.00
Upside: +200.00%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $0.93
Upside: +1,405.38%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.99
Upside: +175.69%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.57
Upside: +211.28%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.68
Upside: +138.10%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.24
Upside: +383.87%